TRAF3 and its biological function

Advances in Experimental Medicine and Biology

Volumn 597, Issue , 2007, Pages 48-59

  He, Jeannie Q ^a   Oganesyan, Gagik ^a   Saha, Supriya K ^a   Zarnegar, Brian ^a   Cheng, Genhong ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; LATENT MEMBRANE PROTEIN 1; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3;

ADAPTIVE IMMUNITY; CYTOKINE PRODUCTION; HUMAN; INNATE IMMUNITY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW;

MUS;

EID: 84934435995     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-70630-6_4     Document Type: Review

References (95)

1. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell 2001; 104(4):487-501.
2. Hehlgans T, Pfeffer K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: Players, rules and the games. Immunology 2005; 115(1):1-20.
3. Rothe M, Wong SC, Henzel WJ et al. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell 1994; 78(4):681-692.
4. Hu HM, O'Rourke K, Boguski MS et al. A novel RING finger protein interacts with the cytoplasmic domain of CD40. J Biol Chem 1994; 269(48):30069-30072.
5. Sato T, Irie S, Reed JC. A novel member of the TRAF family of putative signal transducing proteins binds to the cytosolic domain of CD40. FEBS Lett 1995; 358(2):113-118.
6. Cheng G, Cleary AM, Ye Z et al. Involvement of CRAF1, a Relative of TRAF, in CD40 Signaling. Science 1995; 267:1494-1498.
7. Krajewski S, Zapata JM, Krajewska M et al. Immunohistochemical analysis of in vivo patterns of TRAF-3 expression, a member of the TNF receptor-associated factor family. J Immunol 1997; 159(12):5841-5852.
8. Arch RH, Gedrich RW, Thompson CB. Tumor necrosis factor receptor-associated factors (TRAFs) - a family of adapter proteins that regulates life and death. Genes Dev 1998; 12(18):2821-2830.
9. Chung JY, Park YC, Ye H et al. All TRAFs are not created equal: Common and distinct molecular mechanisms of TRAF-mediated signal transduction. J Cell Sci 2002; 115(Pt 4):679-688.
10. Dempsey PW, Doyle SE, He JQ et al. The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev 2003; 14(3-4):193-209.
11. Inoue J, Ishida T, Tsukamoto N et al. Tumor necrosis factor receptor-associated factor (TRAF) family: Adapter proteins that mediate cytokine signaling. Exp Cell Res 2000; 254(1):14-24.
12. Arch RH, Thompson CB. 4-1BB and Ox40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor kappaB. Mol Cell Biol 1998; 18(1):558-565.
13. Kawamata S, Hori T, Imura A et al. Activation of OX40 signal transduction pathways leads to tumor necrosis factor receptor-associated factor (TRAF) 2- and TRAF5-mediated NF-kappaB activation. J Biol Chem 1998; 273(10):5808-5814.
14. Kwon B, Yu KY, Ni J et al. Identification of a novel activation-inducible protein of the tumor necrosis factor receptor superfamily and its ligand. J Biol Chem 1999; 274(10):6056-6061.
15. Song HY, Regnier CH, Kirschning CJ et al. Tumor necrosis factor (TNF)-mediated kinase cascades: Bifurcation of nuclear factor-κB and c-jun N-terminal kinase (JNK/SAPK) pathways at TNF receptor-associated factor 2. Proc Natl Acad Sci USA 1997; 94(18):9792-9796.
16. Takeuchi M, Rothe M, Goeddel D. Anatomy of TRAF2. Distinct domains for nuclear factor-κB activation and association with tumor necrosis factor signaling proteins. J Biol Chem 1996; 271:19935-19942.
17. Dadgostar H, Cheng G. An intact zinc ring finger is required for tumor necrosis factor receptor-associated factor-mediated nuclear factor-kappaB activation but is dispensable for c-Jun N-terminal kinase signaling. J Biol Chem 1998; 273(38):24775-24780.
18. Dadgostar H, Cheng G. Membrane localization of TRAF 3 enables JNK activation. J Biol Chem 2000; 275:2539-2544.
19. Hostager BS, Bishop GA. Cutting edge: Contrasting roles of TNF receptor-associated factor 2 (TRAF2) and TRAF3 in CD40-activated B lymphocyte differentiation. J Immunol 1999; 162(11):6307-6311.
20. Lee HH, Dempsey PW, Parks TP et al. Specificities of CD40 signaling: Involvement of TRAF2 in CD40-induced NF-kappaB activation and intercellular adhesion molecule-1 up-regulation. Proc Natl Acad Sci USA 1999; 96(4):1421-1426.
21. Xie P, Hostager BS, Bishop GA. Requirement for TRAF3 in signaling by LMP1 but not CD40 in B lymphocytes. J Exp Med 2004; 199(5):661-671.
22. Floettmann JE, Rowe M. Epstein-Barr virus latent membrane protein-1 (LMP1) C-terminus activation region 2 (CTAR2) maps to the far C-terminus and requires oligomerisation for NF-kappaB activation. Oncogene 1997; 15(15):1851-1858.
23. Kieser A, Kaiser C, Hammerschmidt W. LMP1 signal transduction differs substantially from TNF receptor 1 signaling in the molecular functions of TRADD and TRAF2. EMBO J 1999; 18(9):2511-2521.
24. Devergne O, Cahir McFarland ED, Mosialos G et al. Role of the TRAF binding site and NF-kappaB activation in Epstein-Barr virus latent membrane protein 1-induced cell gene expression. J Virol 1998; 72(10):7900-7908.
25. Brown KD, Hostager BS, Bishop GA. Differential signaling and tumor necrosis factor receptor-associated factor (TRAF) degradation mediated by CD40 and the Epstein-Barr virus oncoprotein latent membrane protein 1 (LMP1). J Exp Med 2001; 193(8):943-954.
26. Sandberg M, Hammerschmidt W, Sugden B. Characterization of LMP-1's association with TRAF1, TRAF2, and TRAF3. J Virol 1997; 71(6):4649-4656.
27. Gedrich RW, Gilfillan MC, Duckett CS et al. CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins. J Biol Chem 1996; 271(22):12852-12858.
28. Marsters SA, Ayres TM, Skubatch M et al. Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates the transcription factors NF-kappaB and AP-1. J Biol Chem 1997; 272(22):14029-14032.
29. Park YC, Burkitt V, Villa AR et al. Structural basis for self-association and receptor recognition of human TRAF2. Nature 1999; 398(6727):533-538.
30. Pullen SS, Miller HG, Everdeen DS et al. CD40-tumor necrosis factor receptor-associated factor (TRAF) interactions: Regulation of CD40 signaling through multiple TRAF binding sites and TRAF hetero-oligomerization. Biochemistry 1998; 37(34):11836-11845.
31. Baechler EC, Gregersen PK, Behrens TW. The emerging role of interferon in human systemic lupus erythematosus. Curr Opin Immunol 2004; 16(6):801-807.
32. McWhirter SM, Pullen SS, Holton JM et al. Crystallographic analysis of CD40 recognition and signaling by human TRAF2. Proc Natl Acad Sci USA 1999; 96(15):8408-8413.
33. Ni CZ, Welsh K, Leo E et al. Molecular basis for CD40 signaling mediated by TRAF3. Proc Natl Acad Sci USA 2000; 97(19):10395-10399.
34. Cheng G, Baltimore D. TANK, a coinducer with TRAF2 of TNF- and CD 40L-mediated NF-kappaB activation. Genes Dev 1996; 10(8):963-973.
35. Dadgostar H, Doyle SE, Shahangian A et al. T3JAM, a novel protein that specifically interacts with TRAF3 and promotes the activation of JNK(1). FEBS Lett 2003; 553(3):403-407.
36. Gamper C, van Eyndhoven WG, Schweiger E et al. TRAF-3 interacts with p62 nucleoporin, a component of the nuclear pore central plug that binds classical NLS-containing import complexes. Mol Immunol 2000; 37(1-2):73-84.
37. Ha YJ, Lee JR. Role of TNF receptor-associated factor 3 in the CD40 signaling by production of reactive oxygen species through association with p40phox, a cytosolic subunit of nicotinamide adenine dinucleotide phosphate oxidase. J Immunol 2004; 172(1):231-239.
38. Hsu H, Huang J, Shu HB et al. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity 1996; 4(4):387-396.
39. Hu WH, Mo XM, Walters WM et al. TNAP, a novel repressor of NF-kappaB-inducing kinase, suppresses NF-kappaB activation. J Biol Chem 2004; 279(34):35975-35983.
40. Ling L, Goeddel DV. MIP-T3, a novel protein linking tumor necrosis factor receptor-associated factor 3 to the microtubule network. J Biol Chem 2000; 275(31):23852-23860.
41. Meylan E, Martinon F, Thome M et al. RIP4 (DIK/PKK), a novel member of the RIP kinase family, activates NF-kappa B and is processed during apoptosis. EMBO Rep 2002; 3(12):1201-1208.
42. Nishitoh H, Saitoh M, Mochida Y et al. ASK1 is essential for JNK/SAPK activation by TRAF2. Mol Cell 1998; 2(3):389-395.
43. Pype S, Declercq W, Ibrahimi A et al. TTRAP, a novel protein that associates with CD40, tumor necrosis factor (TNF) receptor-75 and TNF receptor-associated factors (TRAFs), and that inhibits nuclear factor-kappa B activation. J Biol Chem 2000; 275(24):18586-18593.
44. Qian Y, Zhao Z, Jiang Z et al. Role of NF-κB activator Act1 in CD40-mediated signaling in epithelial cells. Proc Natl Acad Sci USA 2002; 99(14):9386-9391.
45. Rothe M, Xiong J, Shu HB et al. I-TRAF is a novel TRAF-interacting protein that regulates TRAF-mediated signal transduction. Proc Natl Acad Sci USA 1996; 93(16):8241-8246.
46. Wong BR, Besser D, Kim N et al. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Molecular Cell 1999; 4(6):1041-1049.
47. Hostager BS, Catlett IM, Bishop GA. Recruitment of CD40 and tumor necrosis factor receptor-associated factors 2 and 3 to membrane microdomains during CD40 signaling. J Biol Chem 2000; 275(20):15392-15398.
48. Xu Y, Cheng G, Baltimore D. Targeted disruption of TRAF3 leads to postnatal lethality and defective T-dependent immune responses. Immunity 1996; 5:407-415.
49. Baeuerle PA, Baltimore D. NF-kappa B: Ten years after. Cell 1996; 87(1):13-20.
50. Kopp EB, Ghosh S. NF-kappa B and rel proteins in innate immunity. Adv Immunol 1995; 58:1-27.
51. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: The control of NF-[kappa] B activity. Annu Rev Immunol 2000; 18:621-663.
52. Zandi E, Karin M. Bridging the gap: Composition, regulation, and physiological function of the IkappaB kinase complex. Mol Cell Biol 1999; 19(7):4547-4551.
53. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev 2004; 18(18):2195-2224.
54. Sizemore N, Lerner N, Dombrowski N et al. Distinct roles of the Ikappa B kinase alpha and beta subunits in liberating nuclear factor kappa B (NF-kappa B) from Ikappa B and in phosphorylating the p65 subunit of NF-kappa B. J Biol Chem 2002; 277(6):3863-3869.
55. Matsushima A, Kaisho T, Rennert PD et al. Essential role of nuclear factor (NF)-kappaB-inducing kinase and inhibitor of kappaB (IkappaB) kinase alpha in NF-kappaB activation through lymphotoxin beta receptor, but not through tumor necrosis factor receptor I. J Exp Med 2001; 193(5):631-636.
56. Yin L, Wu L, Wesche H et al. Defective lymphotoxin-beta receptor-induced NF-kappaB transcriptional activity in NIK-deficient mice. Science 2001; 291(5511):2162-2165.
57. Xiao G, Fong A, Sun SC. Induction of p100 processing by NF-kappaB-inducing kinase involves docking IkappaB kinase alpha (IKKalpha) to p100 and IKKalpha-mediated phosphorylation. J Biol Chem 2004; 279(29):30099-30105.
58. Scheinman RI, Beg AA, Baldwin Jr AS. NF-kappa B p100 (Lyt-10) is a component of H2TF1 and can function as an I kappa B-like molecule. Mol Cell Biol 1993; 13(10):6089-6101.
59. Dejardin E, Droin NM, Delhase M et al. The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity 2002; 17(4):525-535.
60. Hoffmann A, Levchenko A, Scott ML et al. The IkappaB-NF-kappaB signaling module: Temporal control and selective gene activation. Science 2002; 298(5596):1241-1245.
61. Claudio E, Brown K, Park S et al. BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. Nat Immunol 2002; 3(10):958-965.
62. Caamano JH, Rizzo CA, Durham SK et al. Nuclear factor (NF)-kappa B2 (p100/p52) is required for normal splenic microarchitecture and B cell-mediated immune responses. J Exp Med 1998; 187(2):185-196.
63. Yilmaz ZB, Weih DS, Sivakumar V et al. RelB is required for Peyer's patch development: differential regulation of p52-RelB by lymphotoxin and TNF. EMBO J 2003; 22(1):121-130.
64. Coope HJ, Atkinson PG, Huhse B et al. CD40 regulates the processing of NF-kappaB2 p100 to p52. EMBO J 2002; 21(20):5375-5385.
65. Kawabe T, Naka T, Yoshida K et al. The immune responses in CD40-deficient mice: Impaired immunoglobulin class switching and germinal center formation. Immunity 1994; 1(3):167-178.
66. Rennert PD, James D, Mackay F et al. Lymph node genesis is induced by signaling through the lymphotoxin beta receptor. Immunity 1998; 9(1):71-79.
67. Schiemann B, Gommerman JL, Vora K et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001; 293(5537):2111-2114.
68. Liao G, Zhang M, Harhaj EW et al. Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J Biol Chem 2004; 279(25):26243-26250.
69. Hauer J, Puschner S, Ramakrishnan P et al. TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF2/5-mediated activation of the noncanonical NF-kappaB pathway by TRAF-binding TNFRs. Proc Natl Acad Sci USA 2005; 102(8):2874-2879.
70. Hostager BS, Haxhinasto SA, Rowland SL et al. Tumor necrosis factor receptor-associated factor 2 (TRAF2)-deficient B lymphocytes reveal novel roles for TRAF2 in CD40 signaling. J Biol Chem 2003; 278(46):45382-45390.
71. Grech AP, Amesbury M, Chan T et al. TRAF2 differentially regulates the canonical and noncanonical pathways of NF-kappaB activation in mature B cells. Immunity 2004; 21(5):629-642.
72. Sun L, Deng L, Ea CK et al. The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes. Mol Cell 2004; 14(3):289-301.
73. Beg AA, Sha WC, Bronson RT et al. Constitutive NF-kappa B activation, enhanced granulopoiesis, and neonatal lethality in I kappa B alpha-deficient mice. Genes Dev 1995; 9(22):2736-2746.
74. Ishikawa H, Carrasco D, Claudio E et al. Gastric hyperplasia and increased proliferative responses of lymphocytes in mice lacking the COOH-terminal ankyrin domain of NF-kappaB2. J Exp Med 1997; 186(7):999-1014.
75. Oganesyan G, Saha SK, Guo B et al. Critical role of TRAF3 in the Toll-like receptor-dependent and -independent antiviral response. Nature 2006; 439(7073):208-211.
76. Theofilopoulos AN, Baccala R, Beutler B et al. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 2005; 23:307-336.
77. Bowie AG, Haga IR. The role of Toll-like receptors in the host response to viruses. Mol Immunol 2005; 42(8):859-867.
78. Kawai T, Akira S. TLR signaling. Cell Death Differ 2006.
79. Jiang Z, Mak TW, Sen G et al. Toll-like receptor 3-mediated activation of NF-kappaB and IRF3 diverges at Toll-IL-1 receptor domain-containing adapter inducing IFN-beta. Proc Natl Acad Sci USA 2004; 101(10):3533-3538.
80. Chariot A, Leonardi A, Muller J et al. Association of the adaptor TANK with the I kappa B kinase (IKK) regulator NEMO connects IKK complexes with IKK epsilon and TBK1 kinases. J Biol Chem 2002; 277(40):37029-37036.
81. Pomerantz JL, Baltimore D. NF-kappaB activation by a signaling complex containing TRAF2, TANK and TBK1, a novel IKK-related kinase. EMBO J 1999; 18(23):6694-6704.
82. Malmgaard L. Induction and regulation of IFNs during viral infections. J Interferon Cytokine Res 2004; 24(8):439-454.
83. Hemmi H, Takeuchi O, Sato S et al. The roles of two IkappaB kinase-related kinases in lipopolysaccharide and double stranded RNA signaling and viral infection. J Exp Med 2004; 199(12):1641-1650.
84. Perry AK, Chow EK, Goodnough JB et al. Differential requirement for TANK-binding kinase-1 in type I interferon responses to toll-like receptor activation and viral infection. J Exp Med 2004; 199(12):1651-1658.
85. Coccia EM, Severa M, Giacomini E et al. Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol 2004; 34(3):796-805.
86. Colonna M, Krug A, Cella M. Interferon-producing cells: On the front line in immune responses against pathogens. Curr Opin Immunol 2002; 14(3):373-379.
87. Diebold SS, Kaisho T, Hemmi H et al. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004; 303(5663):1529-1531.
88. Heil F, Hemmi H, Hochrein H et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004; 303(5663):1526-1529.
89. Krug A, Luker GD, Barchet W et al. Herpes simplex virus type 1 activates murine natural interferon-producing cells through toll-like receptor 9. Blood 2004; 103(4):1433-1437.
90. Kawai T, Takahashi K, Sato S et al. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat Immunol 2005; 6(10):981-988.
91. Meylan E, Curran J, Hofmann K et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 2005; 437(7062):1167-1172.
92. Seth RB, Sun L, Ea CK et al. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell 2005; 122(5):669-682.
93. Xu LG, Wang YY, Han KJ et al. VISA is an adapter protein required for virus-triggered IFN-beta signaling. Mol Cell 2005; 19(6):727-740.
94. Chen ZJ. Ubiquitin signalling in the NF-kappaB pathway. Nat Cell Biol 2005; 7(8):758-765.
95. Mercurio F, Zhu H, Murray BW et al. IKK-1 and IKK-2: Cytokine-activated IkappaB kinases essential for NF-kappaB activation. Science 1997; 278(5339):860-866.